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Abstract. 
Drug induced liver injury (DILI) is a major challenge in clinical medicine and drug 
development. New models are needed for predicting which potential therapeutic 
compounds will cause DILI in humans, and new markers and mediators of DILI still need 
to be identified. This review will highlight the strengths and weaknesses of using 
zebrafish as a high throughput in vivo model for studying DILI. Although the zebrafish 
liver architecture is different to the mammalian liver, the main physiological processes 
remain similar. Zebrafish metabolize drugs using similar pathways as humans; they 
possess a wide range of cytochrome P450 enzymes enabling metabolic reactions 
including hydroxylation, conjugation, oxidation, demethylation and de-ethylation. 
Following exposure to a range of liver toxic drugs, the zebrafish liver develops 
histological patterns of injury comparable to mammals and liver injury biomarkers can 
be quantified in the zebrafish circulation. The zebrafish immune system is similar to 
mammals, but the zebrafish inflammatory response to DILI is not yet defined. To 
quantify DILI in zebrafish a wide variety of methods can be used including: visual 
assessment, quantification of serum enzymes and experimental serum biomarkers and 
scoring histopathology. With further development, the zebrafish may be a model that 
complements rodents and may have value for the discovery of new disease pathways 
and translational biomarkers. 
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Introduction 
Drug induced liver injury (DILI) is a major problem in clinical medicine and drug 
development. The most common drug causing DILI in the United Kingdom (UK) and the 
United States (USA) is paracetamol (acetaminophen), a commonly used analgesic and 
antipyretic that is safe when used at therapeutic doses. However, when an accidental or 
deliberate overdose occurs, a metabolite of the drug is produced in excess and this can 
lead to potentially fatal hepatocellular necrosis and acute liver failure. Each year 
paracetamol overdose directly results in over 300 deaths in USA [1] and around 150 in 
UK [2]. The antidote, N-acetylcysteine, replenishes cellular glutathione [3] and is highly 
effective at preventing DILI if administered soon after overdose, but its efficacy declines 
substantially with delayed treatment [4]. 
 
Besides challenges with DILI treatment in clinical medicine, in drug development DILI is 
a major safety concern and remains one of the main reasons for denial of drug approval, 
withdrawal of drugs from the market, or “black box” warnings by the USA Food and 
Drug Administration (FDA) [5]. DILI due to paracetamol overdose is dose-dependent 
and, to an extent, predictable from the dose ingested and a timed blood drug 
concentration. By contrast, idiosyncratic liver toxicity is usually identified in late stages 
of drug development or after a new drug has already been released to the marketplace, 
occurring in less than 1 per 10,000-100,000 of subjects who take the medication in 
therapeutic doses [6]. Partly because of its rarity, the pathogenesis of idiosyncratic DILI 
is incompletely understood which makes it hard to predict in earlier drug development 
stages [7]. Therefore, high throughput and improved models are needed for predicting 
human DILI with potential therapeutic compounds and to identify new markers and 
mediators of DILI secondary to established liver toxic drugs such as paracetamol. 
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The zebrafish is a promising animal for assessing drug-induced toxicity in a variety of 
organ systems [8]. Well-established zebrafish assays have frequently been utilised for 
measurement of cardiac function, CNS assessment, gastrointestinal function and 
developmental toxicity [9, 10]. The zebrafish liver can also be used to study drug 
toxicity, however in comparison to other organs, the zebrafish model of liver toxicity has 
been utilised less frequently.  
 
This review will highlight the strengths and weaknesses of zebrafish for studying DILI. 
The use of this model has the potential to identify new drug targets for the treatment of 
DILI and play a role in pre-clinical drug development. Also, the use of zebrafish is in line 
with the 3R’s (reduce, refine, and replace) approach of animal use for scientific purposes 
by replacing higher order animals with lower order zebrafish (particularly zebrafish 
embryos). 
 
Potential advantages of zebrafish as a model for studying DILI 
Histopathology and clinical chemistry have been traditionally used to report liver 
toxicity in established animal models. To decrease the cost and time of toxicity studies, 
alternative test systems have been developed. These include liver slices [11] cultured 
primary hepatocytes [12], immortal hepatic cell lines such as the human hepatoma-
derived HepG2 line [13] and the recently derived human hepatocyte HepaRG line [14]. 
The advantage of these ex vivo and in vitro approaches is that they can be used efficiently 
for high throughput screening. However, the usefulness of these approaches for 
toxicological testing of compounds can be questioned based on differences in gene A
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expression between the different systems [15] and the low sensitivity of the cytotoxicity 
assays, which can be less than 25% for the detection of liver toxic agents [16]. 
To perform liver toxic testing with a higher degree of sensitivity, in vivo assessment is 
necessary. This allows study of a drug’s dose-dependent toxicity within the complex 
physiology of a whole organism. Higher vertebrate organisms (e.q. rodents and pigs) are 
physiologically similar to humans, and have been used for this approach. However, 
smaller, lower order vertebrates, such as the zebrafish (Danio rerio), have similar 
molecular and cellular processes that can accurately model human physiology [8]. In 
addition, the zebrafish offers significant advantages compared to rodents (table 1) and 
other larger animals. The zebrafish embryo is optically transparent and grows outside 
the uterus. This makes it possible to easily detect and monitor developmental changes 
from the single cell stage. For example, the zebrafish embryo has allowed researchers to 
study embryonic lethal phenotypes, something that was not possible with mammalian 
models [17]. Additionally, an early zebrafish embryo, at 3 days post fertilisation (dpf), is 
approximately 3.5mm. This allows zebrafish embryos to be grown in high stocking 
densities in multi-well plates. The high fecundity of the zebrafish - each female can lay 
approximately 200 eggs per week - can generate hundreds of embryos for screening, 
each of which has very rapid development. This reduces the cost of zebrafish husbandry 
significantly, when compared to larger laboratory animals. Furthermore, the Wellcome 
Trust’s Sanger Institute has sequenced the genome of the zebrafish and many of these 
sequences have been annotated  (http://vega.sanger.ac.uk/Danio_rerio/Info/Index)  
[18]. Further advantages of the zebrafish have been described elsewhere in literature 
[10, 19-21].  
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Zebrafish liver anatomy is different to rodents and humans 
Studies examining the zebrafish organs, specifically the liver, have revealed multiple 
similarities with higher vertebrates [22]. When liver budding starts at 28 hours post 
fertilisation (hpf), growth factor and gene expression similar to humans and rodents has 
been reported in zebrafish [23]. When hepatic organogenesis is completed at 72 hpf, the 
liver is perfused with blood and is functional [24]. At 120 hpf, the zebrafish is actively 
seeking food and the yolk sac reserves have become exhausted. By this time, the larval 
fish already has a fully functional liver. In comparison, in the embryonic mouse the 
primary liver bud starts to grow around embryonic day 8.5-9 and the liver is mature at 
embryonic day 18.5, just before birth [25]. The tri-lobed liver of the zebrafish is similar 
to other mammals with regard to biological function. This includes processing of lipids, 
vitamins, proteins and carbohydrates and the synthesis of serum proteins [22]. The 
main difference between the mammalian and zebrafish liver is the structural 
organisation of the liver tissue. Instead of having the large bile ducts, portal veins and 
hepatic arteries organised in portal tracts, these are randomly allocated throughout the 
liver parenchyma in the zebrafish. Hepatocytes in the mammal liver are arranged in 
plates whereas in the zebrafish liver they are arranged in tubules. In zebrafish, the bile 
canaliculi radiate centripetally between hepatocytes to anastomose with a single 
ductular cell forming a ductule at the centre of the tubule. These ductules form a 
network that transports the bile secreted by hepatocytes. Downstream, these ductules 
merge into intrahepatic bile ducts, which converge at the cystic duct, which exits the 
liver at the hilum to connect with the gallbladder. Subsequently, the gallbladder empties 
into the intestine through the common bile duct (figure 1) [23, 26]. The above 
mentioned lack of lobular arrangement impairs morphological differentiation between 
venules from the portal or hepatic vein, as these vessels are histologically identical. 
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Zebrafish drug metabolism is similar to rodents and humans 
One of the key physiological functions of the liver is oxidative catalytic transformation 
which leads to activation or inactivation of many endogenous and exogenous 
compounds. This metabolism is mainly performed by the cytochrome P450 (CYP) 
enzymes, which are predominantly localized in the liver. The metabolic reactions 
performed by the CYP enzymes include oxidation, reduction and hydrolysis. CYPs can be 
divided into two major groups: the first, with generally narrow substrate specificity, are 
predominantly involved in synthesis, activation or inactivation of endogenous 
regulatory molecules. The second group predominantly metabolise xenobiotics, but may 
also metabolise endogenous compounds [27, 28].  
These reactions are divided in two phases, phase I and II. In phase I, the metabolised 
compound is oxidised, reduced or hydrolysed. These phase I reactions are 
predominantly mediated by CYP enzymes. In phase II, conjugation takes place (not CYP 
enzyme mediated). The rate of these reactions is controlled by expression levels and 
activity of the specific enzymes [29].  
When selecting an animal model for toxicity testing, characterization of the metabolic 
properties of the selected species is very important. These properties influence DILI, for 
example, by creating reactive metabolites and this will determine whether a compound 
is toxic [30]. Therefore, the application of zebrafish as a model of human (hepatic) 
endogenous and exogenous compound metabolism requires that the full range of CYP 
genes, these have been identified in zebrafish and annotated with regard to their 
phylogenetic relationships to human CYPs. This essential study was reported by 
Goldstone and colleagues, who characterised a total of 94 CYP genes in the zebrafish 
genome [27]. Based on homologous amino acid sequences, they reported that these A
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genes fitted into 18 CYP gene families that are also present in humans and other 
mammals. CYP families 1-4, that predominantly metabolize exogenous compounds, are 
more diverse in zebrafish than in humans. However, analysis of shared synteny 
demonstrates an evolutionary relationship between human and zebrafish CYP genes. In 
the CYP families 5-51, zebrafish have single genes like humans, and there is a high 
degree of conservation between human and zebrafish sequences [27].  
Metabolism experiments demonstrate that drugs are metabolised when exposed to 
zebrafish embryos by similar reactions to those in humans. An overview of reported 
metabolic experiments is presented in table 2. The metabolic degradation of the widely 
used non-steroidal anti-inflammatory drug ibuprofen is well studied in different 
mammals [31, 32]. The compound is metabolized by different reactions including 
oxidation of the parent compound to hydroxyl-ibuprofen and carboxy-ibuprofen, and 
glucuronic acid conjugation of both parent and metabolite compounds [33]. In humans, 
the oxidation of ibuprofen is catalysed by the CYP2C8/9 isoforms [34]. When ibuprofen 
is exposed to zebrafish embryos, hydroxylated ibuprofen can be detected in the 
zebrafish extracts and water samples, suggesting that zebrafish have an analogous 
metabolic system to the human CYP2C8/9 [35].  
Following exposure to high dose paracetamol, in humans, rat and mice, the reactive 
metabolite N-acetyl-p-benzoquinone imine (NAPQI) is formed by phase I metabolism of 
paracetamol by predominately CYP3A4 [36-38]. Recently, Hui Ting and colleagues, used 
a glutathione trapping assay for NAPQI to determine that zebrafish generate the same 
reactive metabolite as humans. The same authors reported that the zebrafish CYP3A65, 
orthologue for the human CYP3A4, contributed to the formation of NAPQI, as well as the 
phase I hydroxylation of testosterone [39]. A
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Alderton and colleagues [40] confirmed that zebrafish embryos are able to perform the 
metabolic phase I reactions, oxidation, N-demethylation, O-demethylation, and N-
dealkylation as well as the metabolic phase II metabolic reactions sulfation and 
glucuronidation. The metabolites of three compounds were profiled: cisapride, 
verapamil and chlorpromazine. With cisapride, the mammalian phase I reactions 
(piperidine N-delakylation, fluorophenyl ring oxidation), and phase II reactions 
(glucuronidation resulting in glucuronide conjugates) were not observed in zebrafish 
[41]. However, following exposure of zebrafish to verapamil, a number of metabolites 
were formed by N-dealkylation and hydroxylation; these reactions are also present in 
mammals [42]. Three major metabolites of chlorpromazine, which are excreted in 
human urine, were also excreted by zebrafish; these metabolites were formed by 
hydroxylation, oxidation, N-demethylation, glucuronidation and sulfation. Alderton and 
colleagues also reported that zebrafish embryos were able to de-ethylate phenacetin, 
demethylate dextromethorphan and hydroxylate bupropion [40].  
The nuclear receptor, pregnane X receptor (PXR), is involved in the transcriptional 
regulation of cytochrome P4503A (CYP3A) and the multidrug resistance 1 transporter 
(MDR1) [43, 44]. Studies have confirmed that CYP enzymes can be induced and inhibited 
in zebrafish as reported in mammals. Bresolin and colleagues [45], studied the in vivo 
expression of PXR, CYP3A and MDR1 genes in the liver of zebrafish treated with the 
synthetic steroid pregnenolone 16α-carboninitrile (PCN), a potent PXR agonist [46]. The 
liver of the fish treated with PCN had a 1.9-fold increase in PXR followed by a 1.8-fold 
increase of CYP3A and 1.6-fold increase in the MDR1. This suggests that the regulation of 
PXR, CYP3A and MDR1 is conserved in zebrafish and similar to mammals [45].  A
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Tseng and colleagues [47], studied the effect of different drugs on CYP3A expression in 
zebrafish. CYP3A65 expression was upregulated in the embryo (84hpf) intestine by 
rifampicin and dexamethasone. In addition to the PXR pathway, the aryl hydrocarbon 
receptor (AHR2) has a role in the pathway that regulates gene expression and is 
activated by endogenous and exogenous compounds, such as drugs and xenobiotics  
[48]. AHR2 is present in different mammals such as human, mouse and rat and regulates 
expression levels of enzymes involved in phase I metabolism including CYP1A2, CYP1B1 
and aldehyde dehydrogenase 3A1 (ALDH3A1) and phase II metabolism including 
NAD(P)H dehydrogenase quinone 1 (NQO1), UDP glucuronosyltransferase 1A2 
(UGT1A2) and glutathione S-transferase alpha 1 (STA1). [49] Expression of CYP3A65 
was increased by exposing fish to 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD), a AHR2 
ligand [50], during early embryonic stages and inhibition of AHR2 translation by 
antisense morpholino oligonucleotides inhibited both normal and TCDD-stimulated 
CYP3A65 transcription in embryonic intestine. These data suggest that AHR2 regulates 
CYP3A65 expression in zebrafish [47]. 
 
In summary, the zebrafish liver contains enzymes that metabolise a variety of 
endogenous and exogenous compounds in a similar fashion as humans. Additionally, 
these enzymes are subject to similar regulation mechanisms as reported in human. 
These findings support the potential of the zebrafish as animal model for DILI. 
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The zebrafish immune system is similar to rodents and humans 
Hepatic inflammation is commonly reported in various liver diseases, including DILI. 
Liver toxic drugs can have a direct effect on liver cells to release damage associated 
molecular patterns (DAMPS) that stimulate immune cell secretion of chemokines and 
cytokines. Various immune cells such as lymphocytes, neutrophils and macrophages can 
subsequently infiltrate the liver. This complex immune response has been widely 
described by several authors [51-53]. Additionally, specific genetic backgrounds can be 
a risk factor for idiosyncratic DILI in humans [54, 55]. For example, a variety of 
leukocyte antigen (HLA) haplotypes are associated with immunological drug 
hypersensitivity (e.g. amoxicillin/clavulanate and abacavir) [56-59]. 
Many similarities exist between the zebrafish and the mammalian immune system. 
Different studies of haematopoiesis in zebrafish have demonstrated that most, if not all, 
cell types of the human immune system have zebrafish counterparts, although the sites 
of origin differ [60]. There is a variation in the repertoire of chemokine receptors in 
different species, regardless of the specific evolutionary position. Despite this, the 
expression and function of orthologous chemokine receptors in lower and higher 
vertebrates are highly similar [61]. While the zebrafish metabolises drugs using similar 
pathways to humans, whether a similar immune response takes place with DILI in 
zebrafish is yet to be confirmed.  
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A range of drugs induce liver toxicity in zebrafish 
Different methods have been used to assess liver toxicity in zebrafish, for example, 
visual assessment of gross and microscopic morphological changes, serum enzyme and 
biomarker tests, hepatic excretory tests, and assessment of alterations in chemical 
constituents of the liver. 
Gross/subgross visual phenotypic assessment 
The ability to perform assays for liver toxicity with visually assessable phenotypic 
endpoints enables the transparent larval zebrafish to be used in high throughput 
screening. 
A comparative toxic screen of 50 different compounds classified to be liver toxic by USA 
Food and Drug Administration (FDA), and non-toxic controls, was performed in 
zebrafish embryos. The compounds were screened in a researcher-blinded fashion for 
evaluation of three specific phenotypic endpoints of liver toxicity: change in liver size, 
liver morphological abnormality and yolk sac retention. A sensitivity for liver toxic drugs 
of 86% and specificity for non-liver toxic drugs of 77% was reported which resulted in 
an overall correlation of 84% with mammalian in vivo data [62]. However, when 4 
compounds were excluded from the analysis because of low uptake into the embryo 
from the tank water, an increased sensitivity, specificity and overall predictability of 
97%, 77% and 91% was reported [63]. 
He and colleagues [64], exposed zebrafish embryos at 120hpf to 6 known mammalian 
liver toxic drugs (acetaminophen, aspirin, tetracycline HCl, sodium valproate, 
cyclophosphamide and erythromycin) and 2 non-toxic compounds (sucrose and biotin), 
after which 3 phenotypic visual endpoints of liver toxicity were quantitatively assessed. A
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These endpoints were: liver degeneration score, changes in liver size and shape, and 
yolk sac retention. These endpoints were easily measured under a light microscope 
without the need for dissection. All 6 liver toxic compounds induced liver degeneration, 
reduced liver size and delayed yolk sac retention which suggested this assay could be 
predictive for liver toxicity. Zhang and colleagues [65], have developed a transgenic 
zebrafish line (LiPan) that expresses a liver-specific fluorescent protein (DsRed) under 
the fabp10a promoter. They reported that the LiPan line could identify liver toxic drugs 
by  detecting changes in both liver red fluorescence and liver size in a dosage-dependent 
fashion. This was demonstrated by exposing the LiPan line to the liver toxic drugs 
paracetamol, aspirin, isoniazid and phenylbutazone. 
Liver histopathology  
Specific changes in zebrafish histology have been reported: North and colleagues 
reported necrosis after zebrafish were treated with paracetamol [66]. As described in 
other mammals, exposing zebrafish to hexachlorocyclohexane results in specific 
histological changes such as hepatic macrovesicular triglyceride droplets, glycogen 
depletion and the presence of club-shaped mitochondria [67]. Exposure of zebrafish to 
thioacetamide induces steatohepatitis, which is accompanied by the accumulation of 
fatty droplets and apoptosis [68]. Zebrafish exposed to ethanol display histological 
changes such as steatosis, as seen in alcoholic liver disease in human [69]. In conclusion, 
both embryonic and adult zebrafish are amenable to study of the histological changes 
that accompany different liver diseases, such as steatosis, apoptosis and necrosis. 
Circulating biomarkers 
Whilst zebrafish embryos offer a range of advantages that facilitate high throughput 
screening, adult zebrafish are needed if circulating biomarkers are to be measured. A
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Murtha and colleagues determined multiple serum biochemical values in zebrafish (±1 
year old) such as total bilirubin concentration (mean ± SD, 0.38 ± 0.1 mg/dl, range 0.2-
0.6) and serum alanine transaminase (ALT) activity (mean ± SD, 376 ± 25.3 U/L, range 
343 -410) [70]. However, in our laboratory we have reported lower ALT activity (range 
12-137 U/L) in serum from zebrafish (5-24 months old). In a paracetamol induced liver 
toxicity model in adult zebrafish, North and colleagues, demonstrated that ALT activity 
increased in zebrafish in a dose and time dependent fashion [66]. Injury was reduced by 
acetylcysteine treatment of paracetamol exposed zebrafish, as is the case in humans [4]. 
We have observed similar effects of paracetamol on zebrafish in our laboratory. In the 
same model we reported an increase in circulating microRNA-122 concentration, a new 
experimental biomarker for liver toxicity in human [71], in fish with liver injury [72]. 
Cox and colleagues reported that after paracetamol exposure, inhibition of the enzymic 
regulator S-nitrosoglutathione reductase (GSNOR) minimised liver toxicity in zebrafish. 
A GSNOR specific inhibitor improved survival, histology and lowered ALT activity 
through the cytoprotective Nrf2 pathway. Paracetamol toxicity studies in GSNOR-
deficient mice confirmed conservation of the hepatoprotective properties of S-
nitrosothiol signalling across vertebrates [73].This supports the zebrafish being a 
translational model of human paracetamol toxicity and biomarker research.  
Challenges in using zebrafish as a new model for DILI 
 
Although a substantial amount of research demonstrates the potential of zebrafish as a 
model of liver toxicity, there are a number of challenges. 
Zebrafish are often exposed to drug by dissolving the drug in the water which enables 
easy and fast drug administration, this is an advantage of the model that allows for high A
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throughput phenotypic screening, especially if transgenic lines are used [74]. The 
problem with this method of drug administration is that, although the concentration of 
drug in water is known, the amount taken up by the fish is imprecise and variable which 
limits the study of toxicokinetics. Berghmans and colleagues [75], studied the uptake of 
nine compounds in zebrafish embryos by dissolving the compounds in the water and 
found a large variability in the bioavailability of the different compounds. This was 
because the physiochemical properties of different compounds determine the 
absorption of the compounds into the fish through the gills and intestine, rather than 
simply their aqueous concentration. If required, drugs can be injected into the yolk sac 
of embryonic fish and this method can therefore quantify the administered dose at the 
expense of being time-consuming [76].  
The relationship between the drug’s lipophilicity and the amount of compound 
penetrating the zebrafish has been determined [75] however no single physiochemical 
property can accurately predict the uptake of different types of compounds [77]. 
Therefore, bioanalysis should be performed to correlate the amount of drug in the fish 
(the real body burden) and the observed toxic effects [78]. For instance, sodium 
valproate, a potential liver toxic drug in humans did not cause toxic effects in zebrafish 
embryos, possibly due to poor uptake of this drug. In contrast, valproic acid did cause 
liver toxicity in zebrafish embryos with higher blood concentrations, indicating 
increased uptake [62]. To overcome the possible problem of absorption, the amount of 
drug taken up by the fish can be determined by using radio-labelled compound and 
liquid scintillation counting (LSC) or radio high performance liquid chromatography 
(rHPLC). Other methods that determine the uptake of drug into fish include extracting 
the embryos with acetonitrile and then using LCMS-MS analysis [79], and determining 
the uptake of compounds by drawing blood from adult zebrafish and measure the 
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concentration of the compound in blood plasma. However, because of the low blood 
yields obtained from zebrafish, typically 3 to 20 µl of whole blood [80-84], 10 to 20 fish 
may have to be pooled. Zang and colleagues [84], described a recovery method that 
allows for serial blood sampling from adult zebrafish, but it takes one to two weeks for 
fish to recover normal haemoglobin values after taking a small blood sample of 2 µl. This 
delayed recovery may limit the application to toxicity studies. 
Goldstone and colleagues [27], demonstrated that 66 of the 88 studied CYP genes in 
zebrafish embryos have a differential level of expression during development between 3 
hpf through 48 hpf. This stresses the importance of age on toxicity when zebrafish 
embryos are used. In liver toxicity studies, embryos must be >3dpf [27]. Circadian 
rhythms will influence an organism’s susceptibility and responses to xenobiotic 
exposure. It is established that ATP binding cassette (ABC) transporters have a 
significant impact on bio-availability, metabolism and excretion of drugs. The gene 
expression of some transporters, including P-glycoprotein (Pgp), could be under 
circadian transcriptional regulation in zebrafish, as reported in mice [85]. Therefore, 
age-related and circadian-related gene expression profiles will impact on the relative 
higher amount of toxic metabolite, which might influence susceptibility. It is for this 
reason that standardisation of protocols when using embryonic stages are an important 
consideration in high throughput screens. 
Conclusion 
Early identification of liver toxic compounds would accelerate the drug discovery and 
development process and lower the enormous costs. The zebrafish appears to be a 
model that may complement established models. However, before the model can be 
applied on wider scale more validation is needed to confirm the translatability of the A
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model to humans. This may include testing established human liver toxic and non-liver 
toxic compounds, comparing dose responses between fish and humans and developing 
translational biomarkers that bridge between fish, rodents and humans. Furthermore, 
the immunological response observed with DILI in humans has to be studied in 
zebrafish to confirm mechanistic similarity. Ultimately, use of the zebrafish as model for 
DILI is promising and may enable better decision-making in the early stages of drug 
discovery before a compound is tested in higher mammals. 
Declarations 
All authors have completed the Unified Competing Interest form at 
www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) 
and declare no support from any organisation for the submitted work, no financial 
relationships with any organisations that might have an interest in the submitted work 
in the previous 3 years and no other relationships or activities that could appear to have 
influenced the submitted work
A
cc
ep
te
d 
A
rti
cl
e
 
This article is protected by copyright. All rights reserved. 
19 
References 
1. Bronstein AC, Spyker DA, Cantilena LR, Jr., Green J, Rumack BH, Heard SE. 2006 
Annual Report of the American Association of Poison Control Centers' National Poison 
Data System (NPDS). Clin Toxicol (Phila) 2007; 45: 815-917. 
2. Hawton K, Bergen H, Simkin S, Dodd S, Pocock P, Bernal W, Gunnell D, Kapur N. 
Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver 
transplant activity in England and Wales: interrupted time series analyses. BMJ (Clinical 
research ed) 2013; 346: f403. 
3. Lauterburg BH, Corcoran GB, Mitchell JR. Mechanism of action of N-acetylcysteine 
in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Invest 
1983; 71: 980-91. 
4. Rumack BH, Bateman DN. Acetaminophen and acetylcysteine dose and duration: 
past, present and future. Clin Toxicol (Phila) 2012; 50: 91-8. 
5. Temple RJ. Hepatotoxicity through the years: impact on the FDA. 2001. 
http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ucm122149.p
df (last accessed March 2014). 
6. Farrell GC, Liddle C. Drugs and the liver updated, 2002. Semin Liver Dis 2002; 22: 
109-13. 
7. McDonnell ME, Braverman LE. Drug-related hepatotoxicity. N Engl J Med 2006; 
354: 2191-3; author reply 91-3. 
8. Lieschke GJ, Currie PD. Animal models of human disease: zebrafish swim into 
view. Nat Rev Genet 2007; 8: 353-67. 
9. McGrath P, Li CQ. Zebrafish: a predictive model for assessing drug-induced 
toxicity. Drug Discov Today 2008; 13: 394-401. 
10. Barros TP, Alderton WK, Reynolds HM, Roach AG, Berghmans S. Zebrafish: an 
emerging technology for in vivo pharmacological assessment to identify potential safety 
liabilities in early drug discovery. Br J Pharmacol 2008; 154: 1400-13. 
11. Lerche-Langrand C, Toutain HJ. Precision-cut liver slices: characteristics and use 
for in vitro pharmaco-toxicology. Toxicology 2000; 153: 221-53. 
12. LeCluyse EL. Human hepatocyte culture systems for the in vitro evaluation of 
cytochrome P450 expression and regulation. Eur J Pharm Sci 2001; 13: 343-68. 
13. Schoonen WG, Westerink WM, de Roos JA, Debiton E. Cytotoxic effects of 100 
reference compounds on Hep G2 and HeLa cells and of 60 compounds on ECC-1 and CHO 
cells. I mechanistic assays on ROS, glutathione depletion and calcein uptake. Toxicol In 
Vitro 2005; 19: 505-16. 
14. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouet S, Morel F, Guguen-
Guillouzo C, Guillouzo A. Expression of cytochromes P450, conjugating enzymes and 
nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 2006; 34: 75-
83. 
15. Boess F, Kamber M, Romer S, Gasser R, Muller D, Albertini S, Suter L. Gene 
expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices 
compared to the in vivo liver gene expression in rats: possible implications for 
toxicogenomics use of in vitro systems. Toxicol Sci 2003; 73: 386-402. 
16. O'Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR, Gao B, 
Kaludercic N, Angeline A, Bernardi P, Brain P, Hougham C. High concordance of drug-
induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based 
model using high content screening. Arch Toxicol 2006; 80: 580-604. A
cc
ep
te
d 
A
rti
cl
e
 
This article is protected by copyright. All rights reserved. 
20 
17. Chen JN, Haffter P, Odenthal J, Vogelsang E, Brand M, van Eeden FJ, Furutani-Seiki 
M, Granato M, Hammerschmidt M, Heisenberg CP, Jiang YJ, Kane DA, Kelsh RN, Mullins 
MC, Nusslein-Volhard C. Mutations affecting the cardiovascular system and other 
internal organs in zebrafish. Development (Cambridge, England) 1996; 123: 293-302. 
18. Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, Collins JE, 
Humphray S, McLaren K, Matthews L, McLaren S, Sealy I, Caccamo M, Churcher C, Scott 
C, Barrett JC, Koch R, Rauch GJ, White S, Chow W, Kilian B, Quintais LT, Guerra-Assuncao 
JA, Zhou Y, Gu Y, Yen J, Vogel JH, Eyre T, Redmond S, Banerjee R, Chi J, Fu B, Langley E, 
Maguire SF, Laird GK, Lloyd D, Kenyon E, Donaldson S, Sehra H, Almeida-King J, Loveland 
J, Trevanion S, Jones M, Quail M, Willey D, Hunt A, Burton J, Sims S, McLay K, Plumb B, 
Davis J, Clee C, Oliver K, Clark R, Riddle C, Elliot D, Threadgold G, Harden G, Ware D, 
Mortimore B, Kerry G, Heath P, Phillimore B, Tracey A, Corby N, Dunn M, Johnson C, 
Wood J, Clark S, Pelan S, Griffiths G, Smith M, Glithero R, Howden P, Barker N, Stevens C, 
Harley J, Holt K, Panagiotidis G, Lovell J, Beasley H, Henderson C, Gordon D, Auger K, 
Wright D, Collins J, Raisen C, Dyer L, Leung K, Robertson L, Ambridge K, Leongamornlert 
D, McGuire S, Gilderthorp R, Griffiths C, Manthravadi D, Nichol S, Barker G, Whitehead S, 
Kay M, Brown J, Murnane C, Gray E, Humphries M, Sycamore N, Barker D, Saunders D, 
Wallis J, Babbage A, Hammond S, Mashreghi-Mohammadi M, Barr L, Martin S, Wray P, 
Ellington A, Matthews N, Ellwood M, Woodmansey R, Clark G, Cooper J, Tromans A, 
Grafham D, Skuce C, Pandian R, Andrews R, Harrison E, Kimberley A, Garnett J, Fosker N, 
Hall R, Garner P, Kelly D, Bird C, Palmer S, Gehring I, Berger A, Dooley CM, Ersan-Urun Z, 
Eser C, Geiger H, Geisler M, Karotki L, Kirn A, Konantz J, Konantz M, Oberlander M, 
Rudolph-Geiger S, Teucke M, Osoegawa K, Zhu B, Rapp A, Widaa S, Langford C, Yang F, 
Carter NP, Harrow J, Ning Z, Herrero J, Searle SM, Enright A, Geisler R, Plasterk RH, Lee C, 
Westerfield M, de Jong PJ, Zon LI, Postlethwait JH, Nusslein-Volhard C, Hubbard TJ, Roest 
Crollius H, Rogers J, Stemple DL, Begum S, Lloyd C, Lanz C, Raddatz G, Schuster SC. The 
zebrafish reference genome sequence and its relationship to the human genome. Nature 
2013; 496: 498-503. 
19. Briggs JP. The zebrafish: a new model organism for integrative physiology. Am J 
Physiol Regul Integr Comp Physiol 2002; 282: R3-9. 
20. Santoriello C, Zon LI. Hooked! Modeling human disease in zebrafish. J Clin Invest 
2012; 122: 2337-43. 
21. Seth A, Stemple DL, Barroso I. The emerging use of zebrafish to model metabolic 
disease. Dis Model Mech 2013; 6: 1080-8. 
22. Menke AL, Spitsbergen JM, Wolterbeek AP, Woutersen RA. Normal anatomy and 
histology of the adult zebrafish. Toxicol Pathol 2011; 39: 759-75. 
23. Tao T, Peng J. Liver development in zebrafish (Danio rerio). J Genet Genomics 
2009; 36: 325-34. 
24. Isogai S, Horiguchi M, Weinstein BM. The vascular anatomy of the developing 
zebrafish: an atlas of embryonic and early larval development. Dev Biol 2001; 230: 278-
301. 
25. Zhao R, Duncan SA. Embryonic development of the liver. Hepatology (Baltimore, 
Md) 2005; 41: 956-67. 
26. Lorent K, Yeo SY, Oda T, Chandrasekharappa S, Chitnis A, Matthews RP, Pack M. 
Inhibition of Jagged-mediated Notch signaling disrupts zebrafish biliary development 
and generates multi-organ defects compatible with an Alagille syndrome phenocopy. 
Development (Cambridge, England) 2004; 131: 5753-66. A
cc
ep
te
d 
A
rti
cl
e
 
This article is protected by copyright. All rights reserved. 
21 
27. Goldstone JV, McArthur AG, Kubota A, Zanette J, Parente T, Jonsson ME, Nelson 
DR, Stegeman JJ. Identification and developmental expression of the full complement of 
Cytochrome P450 genes in Zebrafish. BMC Genomics 2010; 11: 643. 
28. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous 
signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006; 6: 947-60. 
29. Williams RT. The metabolism of certain drugs and food chemicals in man. Ann N 
Y Acad Sci 1971; 179: 141-54. 
30. Park BK, Boobis A, Clarke S, Goldring CE, Jones D, Kenna JG, Lambert C, Laverty 
HG, Naisbitt DJ, Nelson S, Nicoll-Griffith DA, Obach RS, Routledge P, Smith DA, Tweedie 
DJ, Vermeulen N, Williams DP, Wilson ID, Baillie TA. Managing the challenge of 
chemically reactive metabolites in drug development. Nat Rev Drug Discov 2011; 10: 
292-306. 
31. Adams SS, Bough RG, Cliffe EE, Lessel B, Mills RF. Absorption, distribution and 
toxicity of ibuprofen. Toxicol Appl Pharmacol 1969; 15: 310-30. 
32. Smith HS, Voss B. Pharmacokinetics of intravenous ibuprofen: implications of 
time of infusion in the treatment of pain and fever. Drugs 2012; 72: 327-37. 
33. Kepp DR, Sidelmann UG, Tjornelund J, Hansen SH. Simultaneous quantitative 
determination of the major phase I and II metabolites of ibuprofen in biological fluids by 
high-performance liquid chromatography on dynamically modified silica. J Chromatogr 
B Biomed Sci Appl 1997; 696: 235-41. 
34. Brown CM, Reisfeld B, Mayeno AN. Cytochromes P450: a structure-based 
summary of biotransformations using representative substrates. Drug Metab Rev 2008; 
40: 1-100. 
35. Jones HS, Trollope HT, Hutchinson TH, Panter GH, Chipman JK. Metabolism of 
ibuprofen in zebrafish larvae. Xenobiotica 2012; 42: 1069-75. 
36. Dahlin DC, Miwa GT, Lu AY, Nelson SD. N-acetyl-p-benzoquinone imine: a 
cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci U S 
A 1984; 81: 1327-31. 
37. Laine JE, Auriola S, Pasanen M, Juvonen RO. Acetaminophen bioactivation by 
human cytochrome P450 enzymes and animal microsomes. Xenobiotica 2009; 39: 11-
21. 
38. Jemnitz K, Veres Z, Monostory K, Kobori L, Vereczkey L. Interspecies differences 
in acetaminophen sensitivity of human, rat, and mouse primary hepatocytes. Toxicol In 
Vitro 2008; 22: 961-7. 
39. Chng HT, Ho HK, Yap CW, Lam SH, Chan EC. An investigation of the bioactivation 
potential and metabolism profile of Zebrafish versus human. J Biomol Screen 2012; 17: 
974-86. 
40. Alderton W, Berghmans S, Butler P, Chassaing H, Fleming A, Golder Z, Richards F, 
Gardner I. Accumulation and metabolism of drugs and CYP probe substrates in zebrafish 
larvae. Xenobiotica 2010; 40: 547-57. 
41. Meuldermans W, Van Peer A, Hendrickx J, Lauwers W, Swysen E, Bockx M, 
Woestenborghs R, Heykants J. Excretion and biotransformation of cisapride in dogs and 
humans after oral administration. Drug Metab Dispos 1988; 16: 403-9. 
42. Eichelbaum M, Ende M, Remberg G, Schomerus M, Dengler HJ. The metabolism of 
DL-[14C]verapamil in man. Drug Metab Dispos 1979; 7: 145-8. 
43. Mani S, Dou W, Redinbo MR. PXR antagonists and implication in drug metabolism. 
Drug Metab Rev 2013; 45: 60-72. A
cc
ep
te
d 
A
rti
cl
e
 
This article is protected by copyright. All rights reserved. 
22 
44. Li F, Lu J, Cheng J, Wang L, Matsubara T, Csanaky IL, Klaassen CD, Gonzalez FJ, Ma 
X. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-
therapy. Nat Med 2013; 19: 418-20. 
45. Bresolin T, de Freitas Rebelo M, Celso Dias Bainy A. Expression of PXR, CYP3A 
and MDR1 genes in liver of zebrafish. Comp Biochem Physiol C Toxicol Pharmacol 2005; 
140: 403-7. 
46. Moore LB, Maglich JM, McKee DD, Wisely B, Willson TM, Kliewer SA, Lambert MH, 
Moore JT. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and 
benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear 
receptors. Mol Endocrinol 2002; 16: 977-86. 
47. Tseng HP, Hseu TH, Buhler DR, Wang WD, Hu CH. Constitutive and xenobiotics-
induced expression of a novel CYP3A gene from zebrafish larva. Toxicol Appl Pharmacol 
2005; 205: 247-58. 
48. Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport 
by xenobiotics. Arch Pharm Res 2005; 28: 249-68. 
49. Rowlands JC, Gustafsson JA. Aryl hydrocarbon receptor-mediated signal 
transduction. Crit Rev Toxicol 1997; 27: 109-34. 
50. Poellinger L, Gottlicher M, Gustafsson JA. The dioxin and peroxisome proliferator-
activated receptors: nuclear receptors in search of endogenous ligands. Trends 
Pharmacol Sci 1992; 13: 241-5. 
51. Tian Z, Chen Y, Gao B. Natural killer cells in liver disease. Hepatology (Baltimore, 
Md) 2013; 57: 1654-62. 
52. Jaeschke H, Williams CD, Ramachandran A, Bajt ML. Acetaminophen 
hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int 
2012; 32: 8-20. 
53. Ju C, Reilly T. Role of immune reactions in drug-induced liver injury (DILI). Drug 
Metab Rev 2012; 44: 107-15. 
54. Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, 
Krauss RM. Identifying genetic risk factors for serious adverse drug reactions: current 
progress and challenges. Nat Rev Drug Discov 2007; 6: 904-16. 
55. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev 
Pharmacol Toxicol 2007; 47: 513-39. 
56. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, 
Goldstein DB, John S, Nelson MR, Graham J, Park BK, Dillon JF, Bernal W, Cordell HJ, 
Pirmohamed M, Aithal GP, Day CP. HLA-B*5701 genotype is a major determinant of 
drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-9. 
57. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, Day CP, 
Aithal GP. Human leucocyte antigen class II genotype in susceptibility and resistance to 
co-amoxiclav-induced liver injury. J Hepatol 2010; 53: 1049-53. 
58. Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F, Phillips 
E, Christiansen FT, Purcell AW, McCluskey J, Mallal S. Predisposition to abacavir 
hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc 
Natl Acad Sci U S A 2004; 101: 4180-5. 
59. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, 
Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-
B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase 
inhibitor abacavir. Lancet 2002; 359: 727-32. 
60. Berman J, Hsu K, Look AT. Zebrafish as a model organism for blood diseases. Br J 
Haematol 2003; 123: 568-76. A
cc
ep
te
d 
A
rti
cl
e
 
This article is protected by copyright. All rights reserved. 
23 
61. Bajoghli B. Evolution and function of chemokine receptors in the immune system 
of lower vertebrates. Eur J Immunol 2013; 43: 1686-92. 
62. Jones M, Ball JS, Dodd A, Hill AJ. Comparison between zebrafish and Hep G2 
assays for the predictive identification of hepatotoxins. Toxicology 2009; 262: 13-14. 
63. Hill A, Mesens N, Steemans M, Xu JJ, Aleo MD. Comparisons between in vitro 
whole cell imaging and in vivo zebrafish-based approaches for identifying potential 
human hepatotoxicants earlier in pharmaceutical development. Drug Metab Rev 2012; 
44: 127-40. 
64. He JH, Guo SY, Zhu F, Zhu JJ, Chen YX, Huang CJ, Gao JM, Dong QX, Xuan YX, Li CQ. 
A zebrafish phenotypic assay for assessing drug-induced hepatotoxicity. J Pharmacol 
Toxicol Methods 2013; 67: 25-32. 
65. Zhang X, Li C, Gong Z. Development of a Convenient In Vivo Hepatotoxin Assay 
Using a Transgenic Zebrafish Line with Liver-Specific DsRed Expression. PloS one 2014; 
9: e91874. 
66. North TE, Babu IR, Vedder LM, Lord AM, Wishnok JS, Tannenbaum SR, Zon LI, 
Goessling W. PGE2-regulated wnt signaling and N-acetylcysteine are synergistically 
hepatoprotective in zebrafish acetaminophen injury. Proc Natl Acad Sci U S A 2010; 107: 
17315-20. 
67. Braunbeck T, Gorge G, Storch V, Nagel R. Hepatic steatosis in zebra fish 
(Brachydanio rerio) induced by long-term exposure to gamma-hexachlorocyclohexane. 
Ecotoxicol Environ Saf 1990; 19: 355-74. 
68. Amali AA, Rekha RD, Lin CJ, Wang WL, Gong HY, Her GM, Wu JL. Thioacetamide 
induced liver damage in zebrafish embryo as a disease model for steatohepatitis. J 
Biomed Sci 2006; 13: 225-32. 
69. Passeri MJ, Cinaroglu A, Gao C, Sadler KC. Hepatic steatosis in response to acute 
alcohol exposure in zebrafish requires sterol regulatory element binding protein 
activation. Hepatology (Baltimore, Md) 2009; 49: 443-52. 
70. Murtha JM, Qi W, Keller ET. Hematologic and serum biochemical values for 
zebrafish (Danio rerio). Comp Med 2003; 53: 37-41. 
71. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, French NS, 
Dhaun N, Webb DJ, Costello EM, Neoptolemos JP, Moggs J, Goldring CE, Park BK. 
Circulating microRNAs as potential markers of human drug-induced liver injury. 
Hepatology (Baltimore, Md) 2011; 54: 1767-76. 
72. Vliegenthart AD, Starkey Lewis P, Tucker CS, Del Pozo J, Rider S, Antoine DJ, 
Dubost V, Westphal M, Moulin P, Bailey MA, Moggs JG, Goldring CE, Park BK, Dear JW. 
Retro-orbital Blood Acquisition Facilitates Circulating microRNA Measurement in 
Zebrafish with Paracetamol Hepatotoxicity. Zebrafish 2014. Published online.  
73. Cox AG, Saunders DC, Kelsey PB, Jr., Conway AA, Tesmenitsky Y, Marchini JF, 
Brown KK, Stamler JS, Colagiovanni DB, Rosenthal GJ, Croce KJ, North TE, Goessling W. S-
nitrosothiol signaling regulates liver development and improves outcome following 
toxic liver injury. Cell reports 2014; 6: 56-69. 
74. Burns CG, Milan DJ, Grande EJ, Rottbauer W, MacRae CA, Fishman MC. High-
throughput assay for small molecules that modulate zebrafish embryonic heart rate. Nat 
Chem Biol 2005; 1: 263-4. 
75. Berghmans S, Butler P, Goldsmith P, Waldron G, Gardner I, Golder Z, Richards FM, 
Kimber G, Roach A, Alderton W, Fleming A. Zebrafish based assays for the assessment of 
cardiac, visual and gut function--potential safety screens for early drug discovery. J 
Pharmacol Toxicol Methods 2008; 58: 59-68. A
cc
ep
te
d 
A
rti
cl
e
 
This article is protected by copyright. All rights reserved. 
24 
76. Langheinrich U. Zebrafish: a new model on the pharmaceutical catwalk. Bioessays 
2003; 25: 904-12. 
77. Doshna C, Benbow J, Depasquale M, Okerberg C, Turnquist S, Stedman D, Chapin 
R, Sivaraman L, Waldron G, Navetta K, Brady J, Banker M, Casimiro-Garcia A, Hill A, Jones 
M, Ball J, Aleo M. Multi-phase analysis of uptake and toxicity in Zebrafish: Relationship to 
compound physical-chemical properties. Toxicol Sci 2009; 108. 
78. Van den Bulck K, Hill A, Mesens N, Diekman H, De Schaepdrijver L, Lammens L. 
Zebrafish developmental toxicity assay: A fishy solution to reproductive toxicity 
screening, or just a red herring? Reprod Toxicol 2011; 32: 213-9. 
79. Diekmann H, Hill A. ADMETox in zebrafish. Drug Discov Today Dis Models 2013; 
10: e31-e35. 
80. Babaei F, Ramalingam R, Tavendale A, Liang Y, Yan LS, Ajuh P, Cheng SH, Lam YW. 
Novel Blood Collection Method Allows Plasma Proteome Analysis from Single Zebrafish. 
J Proteome Res 2013. 
81. Jagadeeswaran P, Sheehan JP, Craig FE, Troyer D. Identification and 
characterization of zebrafish thrombocytes. Br J Haematol 1999; 107: 731-8. 
82. Eames SC, Philipson LH, Prince VE, Kinkel MD. Blood sugar measurement in 
zebrafish reveals dynamics of glucose homeostasis. Zebrafish 2010; 7: 205-13. 
83. Pedroso GL, Hammes TO, Escobar TD, Fracasso LB, Forgiarini LF, da Silveira TR. 
Blood collection for biochemical analysis in adult zebrafish. J Vis Exp 2012: e3865. 
84. Zang L, Shimada Y, Nishimura Y, Tanaka T, Nishimura N. A novel, reliable method 
for repeated blood collection from aquarium fish. Zebrafish 2013; 10: 425-32. 
85. Ando H, Yanagihara H, Sugimoto K, Hayashi Y, Tsuruoka S, Takamura T, Kaneko S, 
Fujimura A. Daily rhythms of P-glycoprotein expression in mice. Chronobiol Int 2005; 
22: 655-65. 
 
A
cc
ep
te
d 
A
rti
cl
e
 
This article is protected by copyright. All rights reserved. 
25 
 
Legends to tables/figures 
Table 1  Comparative advantages of using zebrafish and mice to model DILI 
 
Table 2 Specific metabolic drug reactions reported in zebrafish compared with 
humans.  
 
Figure 1  Schematic transverse representations of mammalian and zebrafish liver 
architecture (A) The mammalian liver lobule. Arranged with plates of 
hepatocytes radiating outward from a central vein (CV). At the corners of 
each lobule are portal tracts (PT) containing a portal vein (PV), hepatic 
artery (HA) and a bile duct (BD). (B) Mammalian bilayered hepatocyte 
plate. Bicellular canaliculi (CA) are located adjacent to the hepatocytes (H) 
in the hepatocyte plate (HP), a basal hepatocyte membrane allows 
transport of oxygen, proteins and different macromolecules to the 
hepatocytes. Blood enters the liver through the portal vein and hepatic 
artery after which it enters the central vein through sinusoid vessels, 
located between the plates. (C) The zebrafish liver architecture. The portal 
vein (PV), hepatic artery (HA), bile ducts (BD), hepatocyte tubule (HT) and 
the central vein (CV) are scattered throughout the parenchyma. (D) 
Zebrafish hepatocytes (H) are arranged in tubules around small bile ducts, 
which receive bile from the hepatocyte canaliculi (CA). Sinusoids are A
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located at the periphery of these tubules (E) Histological image of male 
zebrafish liver (H&E staining at x200). Note the presence of several biliary 
ducts (arrows), bile ductules (arrowheads), and blood vessels (*) with lack 
of lobular arrangement. (F) Histological image of female zebrafish liver 
(H&E staining at x400). This high power image displays sinusoidal spaces 
between hepatocytes (arrows), and an instance of the tubular 
arrangement of hepatocytes (encircled), which is frequently not visible 
histologically. Note the difference in staining of male and female zebrafish 
liver. 
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Advantages of zebrafish Advantages of mice 
Optically large and transparent embryos Characterized inbred strains, including knock-out and knock-in strains 
Ex utero development Complement of all mammalian organs and physiological similarity to humans 
Similar cellular and sub-cellular processes to humans Easier to draw blood than fish 
Rapid development of liver ~72-96 hpf Feasible to perform pharmaco/toxico kinetic studies 
High fecundity (~200 eggs/female/week) Genome duplication of fish results in multiple copies of genes 
Large numbers of fish can be easily maintained  
Embryonic fish can survive up to 7 days without a Cardiovascular system  
Low overall cost  
Easy drug delivery by dissolving in the tank water, with possibility of drug delivery by microinjection  
Feasibility of high throughput screens  
High n numbers available per study, allowing improved statistical analysis  
Lower order mammal (in line with 3R principle) 
 
Table 1 
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Drug metabolism in zebrafish     
Compound Reaction observed in zebrafish Similar to human Human P450 isotype  Ref 
Ibuprofen Hydroxylation Yes CYP2C8/9 [33] 
Paracetamol Hydroxylation Yes CYP3A4 [37] 
Testosterone Hydroxylation Yes CYP3A4 [37] 
Cisapride Sulphate conjugation No CYP3A4 [38] 
Verapamil N-dealkylation and Hydroxylation Yes CYP3A4, CYP2C8/9, CYP1A2 [38] 
Chlorpromazine Hydroxylation, Oxidation, N-Demethylation, 
Glucuronidation and Sulfation 
Yes CYP1A2, CYP2D6 [38] 
Phenacetin De-ethylation Yes CYP1A2 [38] 
Dextromethorphan Demethylate Yes CYP2D6 [38] 
Bupropion Hydroxylation Yes CYP2B6 [38] 
 
Table 2 
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